Mothaffar Rimawi, MD, on HR-Positive, HER2-Positive Breast Cancer: Results of the NRG Oncology/NSABP B-52 Trial
2016 San Antonio Breast Cancer Symposium
Mothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-positive, HER2-positive disease treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation (Abstract S3-06).
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).
Joseph A. Sparano, MD, of the Montefiore Medical Center, discusses the tumor microenvironment of metastasis score and its association with early distant recurrence in HR-positive, HER2-negative early-stage breast cancer (Abstract S4-04).
To view a short film on capturing imaging inside breast cancer tumors, go to: https://www.youtube.com/watch?v=q_JDp-VePAs
Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data into clinical practice.
Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings from a session Dr. O’Regan moderated on three major trials addressing anastrozole after tamoxifen in HR-positive early breast cancer, letrozole in HR-positive disease, and extended letrozole treatment after adjuvant endocrine therapy (Abstracts S1-03, S1-05, S1-08).
Sara A. Hurvitz, MD, of the UCLA Jonsson Comprehensive Cancer Center, discusses findings on the biological effects of abemaciclib in a neoadjuvant study for postmenopausal patients (Abstract S4-06).